Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $14.75

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been given an average rating of “Moderate Buy” by the five analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $14.75.

Several equities research analysts have issued reports on the company. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Tuesday, May 27th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 price objective on shares of DBV Technologies in a research report on Thursday, June 26th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. The Goldman Sachs Group upgraded shares of DBV Technologies to a “sell” rating and set a $7.25 price target for the company in a report on Thursday, May 29th. Finally, Lifesci Capital upgraded shares of DBV Technologies to a “strong-buy” rating in a report on Thursday, June 26th.

DBV Technologies Stock Performance

DBVT opened at $9.87 on Wednesday. The firm’s fifty day moving average is $9.73 and its two-hundred day moving average is $8.49. The firm has a market cap of $270.44 million, a PE ratio of -2.07 and a beta of -0.36. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.34). The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. Equities analysts forecast that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Nan Fung Trinity HK Ltd. acquired a new stake in shares of DBV Technologies in the 2nd quarter valued at approximately $340,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies in the 2nd quarter valued at about $9,315,000. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies during the 2nd quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Finally, Vivo Capital LLC bought a new position in DBV Technologies during the second quarter worth about $9,659,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.